E-ISSN 2577-5669
 

Research Article 


The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI.

Abstract
Objectives: This study focuses on the severity of the adverse effects induced by monoclonal antibodies in Indian population. This study is performed in a multispecialty hospital and adverse effects were monitored in the study population. Therefore, the main objective of the study was active surveillance of adverse effects induced by monoclonal antibodies.
Methodology: A cohort study was conducted in 120 patients with breast and gynaecological cancer for a period of 6 months in a multispecialty hospital.
Result: Among 120 patients Breast cancer was the most prevalent followed by cervical cancer. Adverse effects were seen in all age groups, most adverse effects were reported with Trastuzumab (37.50%) and Bevacizumab (26.78%). Monoclonal antibodies were well tolerated by the patients with minimum adverse effects which are manageable with supportive therapy, the most prevalent adverse effect was anaemia.
Conclusion: By assessing Adverse effects using Naranjo scale, most of them were found to be possible (32%) and probable (67%). In WHO scale, the most of the adverse effects were also follow under category of possible (38.14%) and probable (61.20%). Of all adverse effects no severe adverse effects were seen in the patients, i.e. monoclonal antibodies were well tolerated by the patients.

Key words: Naranjo Scale, WHO Scale, Monoclonal Antibodies, Breast cancer, Gynaecological cancers


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by AMIRHOSSEIN SETAYESH
Articles by GOPINATH ELUMALAI
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. J Complement Med Res. 2021; 12(4): 148-163. doi:10.5455/jcmr.2021.12.04.24


Web Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. https://www.jocmr.com/?mno=140638 [Access: April 25, 2022]. doi:10.5455/jcmr.2021.12.04.24


AMA (American Medical Association) Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. J Complement Med Res. 2021; 12(4): 148-163. doi:10.5455/jcmr.2021.12.04.24



Vancouver/ICMJE Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. J Complement Med Res. (2021), [cited April 25, 2022]; 12(4): 148-163. doi:10.5455/jcmr.2021.12.04.24



Harvard Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI (2021) The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. J Complement Med Res, 12 (4), 148-163. doi:10.5455/jcmr.2021.12.04.24



Turabian Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. 2021. The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. Journal of Complementary Medicine Research, 12 (4), 148-163. doi:10.5455/jcmr.2021.12.04.24



Chicago Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. "The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients." Journal of Complementary Medicine Research 12 (2021), 148-163. doi:10.5455/jcmr.2021.12.04.24



MLA (The Modern Language Association) Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI. "The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients." Journal of Complementary Medicine Research 12.4 (2021), 148-163. Print. doi:10.5455/jcmr.2021.12.04.24



APA (American Psychological Association) Style

AMIRHOSSEIN SETAYESH, GOPINATH ELUMALAI (2021) The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients. Journal of Complementary Medicine Research, 12 (4), 148-163. doi:10.5455/jcmr.2021.12.04.24